Повышенный холестерин. Профилактика и лечение атеросклероза

59. Lejskova M., Alušík S., Valenta Z., Adámkova S., Pitha J. (2012). Natural postmenopause is associated with an increase in combined cardiovascular risk factors. Physiol. Res. 6, 587–596.

60. Christine M. Williams, Karen Maunder, D. Theale. (1989). The effect of a low-fat diet on luteal-phase prolactin and oestradiol concentrations and erythrocyte phospholipids in normal premenopausal women. Br J Nutr. 61, 651–661.

61. Xiaohui Cui, Bernard Rosner, Walter C. Willett, Susan E. Hankinson. (2010). Dietary Fat, Fiber, and Carbohydrate Intake and Endogenous Hormone Levels in Premenopausal Women. HORM CANC. 1, 265–276.

62. Холестерин // Большая советская энциклопедия: [в 30 т.] / гл. ред. А. М. Прохоров. – 3-е изд. – М.: Советская энциклопедия, 1969–1978.

63. PubMed – NCBI Steroidogenic enzymes: structure, function, and role in regulation of steroid hormone biosynthesis.

64. Ленинджер А. 1976. Биохимия. М.: «Мир».

65. André Tchernof, Fernand Labrie, Alain Bélanger, Denis Prud’homme, Claude Bouchard, et. al.. (1997). Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis. 133, 235–244).

66. Кольман Я., Рём К.-Г., «Наглядная биохимия», пер. с нем., М., «Мир», 2009.

67. Frank M Sacks, Martijn Katan. (2002). Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. The American Journal of Medicine. 113, 13–24.

68. Classics in arteriosclerosis research: On experimental cholesterin steatosis and its significance in the origin of some pathological processes by N. Anitschkow and S. Chalatow, translated by Mary Z. Pelias, 1913. Arteriosclerosis, Thrombosis, and Vascular Biology. 3, 178-182.

69. Ежов М. В., Сергиенко И. В., Рожкова Т. А., Кухарчук В. В., Коновалов Г. А., Мешков А. Н., Ершова А. И., Гуревич В. С., Константинов В. О., Соколов А. А., Щербакова М. Ю., Леонтьева И. В., Бажан С. С., Воевода М. И., Шапошник И. И. Российские рекомендации по диагностике и лечению семейной гиперхолестеринемии. Атеросклероз и дислипидемии. 2016; 4: 21-9.

70. Yuan G., Wang J., Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ. 2006 Apr 11; 174 (8): 1124-9.

71. Goldberg AC., Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adultpatients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5 (3 Suppl): S1-8. doi:10.1016/j.jacl.2011.04.003. Epub 2011 Apr 12.

72. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004 Mar; 173 (1): 55–68.

73. Кухарчук В. В., Малышев П. П., Мешков А. Н. Семейная гиперхолестеринемия: современные аспекты диагностики, профилактики и терапии. Кардиология. 2009; 49 (1): 76–83.

74. Yuan G, Wang J., Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ. 2006 Apr 11; 174 (8): 1124-9.

75. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on FamilialHypercholesterolemia. J Clin Lipidol. 2011 Jun; 5 (3 Suppl): S9-17.

76. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 1993 Dec; 104 (1–2): 1-18.

77. Merino-Ibarra E., Castillo S., Mozas P., Cenarro A., Martorell E., Díaz JL, Suarez-Tembra M., Alonso R., Civeira F., Mata P., Pocoví M.. Screening of APOB gene mutations in subjects with clinical diagnosis of familialhypercholesterolemia. Hum Biol. 2005 Oct; 77 (5): 663-73.

78. Soufi M., Sattler AM, Maerz W., Starke A., Herzum M., Maisch B., Schaefer JR. A new but frequent mutation of apoB-100-apoB His3543Tyr. Atherosclerosis. 2004 May; 74 (1): 11.

79. Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev. 2008 Feb; 29 (1): 11-2.

80. Мандельштам, М. Ю., Васильев В. Б. Моногенные гиперхолестеринемии: новые гены, новые мишени для лечения. Генетика. – 2008. – Т. 44, N 10. – С. 1309–1316.

81. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA. 2005 Feb 8; 102 (6): 2069-74.